#214168

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

By |2025-01-06T09:01:29-06:00January 6, 2025|Press Release|0 Comments
Read More

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

By |2025-01-02T08:50:27-06:00December 9, 2024|Press Release|0 Comments
Read More

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

By |2024-06-26T11:43:52-05:00June 26, 2024|Press Release|0 Comments
Read More

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By |2024-01-01T17:33:51-06:00January 3, 2024|Press Release|0 Comments
Read More

Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By |2024-01-01T17:34:44-06:00January 2, 2024|Press Release|0 Comments
Read More

Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair

SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

By |2023-12-05T09:51:39-06:00December 5, 2023|Press Release|0 Comments
Read More

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...

By |2023-09-04T22:05:36-05:00September 5, 2023|Press Release|0 Comments
Read More

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...

By |2023-05-22T22:49:30-05:00May 23, 2023|Press Release|0 Comments
Read More

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...

By |2023-05-05T09:50:48-05:00April 6, 2023|Press Release|0 Comments
Read More

© 2025 STAR Therapeutics Inc.

THANK YOU

We look forward to connecting with you